Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02682823 · ClinicalTrials.gov registry record · Phase 4
Tocilizumab Real-Life Human Factors (RLHFs) Validation Study
A Phase 4 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 4
- Development phase
- 91
- Enrollment target
NCT02682823 is a Phase 4 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 91 participants.
The verdict
NCT02682823, a Phase 4 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 91 participants
- Enrollment target
Study Summary
This study is designed to evaluate RLHFs concerning administration of the tocilizumab autoinjector AI-1000 G2 in adults with rheumatoid arthritis (RA) who have been receiving subcutaneous (SC) tocilizumab using the commercially available prefilled syringe and needle safety device (PFS-NSD). The study will enroll participants with RA, a subset of whom will be assigned to perform self-injection with the AI-1000 G2. Enrolled caregivers (CGs) and healthcare professionals (HCPs) will administer the AI-1000 G2 injection to the remaining study participants.
Interventions
- DRUG Tocilizumab
- DEVICE AI-1000 G2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2016-03-21 |
| Est. Completion | 2016-07-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02682823
The ClinicalTrials.gov registry entry for NCT02682823 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tocilizumab is the first listed.
NCT02682823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02682823 about?
NCT02682823 is a clinical study titled "Tocilizumab Real-Life Human Factors (RLHFs) Validation Study". This study is designed to evaluate RLHFs concerning administration of the tocilizumab autoinjector AI-1000 G2 in adults with rheumatoid arthritis (RA) who have been receiving subcutaneous (SC) tocilizumab using the commercially available prefilled syringe and needle safety device (PFS-NSD). The stud...
What is the current status of trial NCT02682823?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 91 participants. The study started on 2016-03-21. Estimated completion is 2016-07-29.
What interventions are being tested in trial NCT02682823?
The interventions under investigation include: Tocilizumab (DRUG), AI-1000 G2 (DEVICE).
Who is sponsoring clinical trial NCT02682823?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.